Loading
Lung Cancer Research Studies / Lung Cancer Treatments and Mutations · Journal article
Medicinal Chemistry Research · August 18, 2026
An action by a regulator. Authoritative on labelling and availability.
Zidesamtinib (Jideytro) received FDA accelerated approval on July 22, 2026, for previously treated ROS1-positive NSCLC based on phase 1/2 data demonstrating durable efficacy and safety, including activity in CNS metastases and against the G2032R resistance mutation. This is a regulatory milestone, not a comparative clinical trial outcome.
Phase 1/2 trial (ARROS-1). Previously treated patients with ROS1-positive NSCLC, including those with CNS metastases. Intervention: Zidesamtinib (Jideytro, NVL-520) 100 mg once daily, orally.
Phase 1/2 ARROS-1 trial showed durable clinical efficacy and manageable safety in previously treated ROS1-positive NSCLC Activity demonstrated in patients with CNS metastases Coverage of G2032R resistance mutation achieved
Phase 1/2 ARROS-1 trial showed durable clinical efficacy and manageable safety in previously treated ROS1-positive NSCLC Oral dose 100 mg once daily exhibits favorable pharmacokinetic profile
This regulatory approval establishes zidesamtinib as a treatment option for ROS1-positive NSCLC patients who have progressed on prior ROS1-targeted therapies. The brain penetrance and resistance mutation coverage address key clinical limitations of earlier agents, particularly for CNS disease and acquired resistance.
FDA accelerated approval of zidesamtinib for ROS1-positive NSCLC in treatment-experienced patients, based on phase 1/2 trial data showing durable efficacy and manageable safety.
As stated by the source record.
Quoted from the source exactly as published.
This regulatory approval establishes zidesamtinib as a treatment option for ROS1-positive NSCLC patients who have progressed on prior ROS1-targeted therapies. The brain penetrance and resistance mutation coverage address key clinical limitations of earlier agents, particularly for CNS disease and acquired resistance.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
ROS1-targeted therapies have improved outcomes in ROS1-positive non-small cell lung cancer (NSCLC), but acquired resistance, CNS progression, and off-target toxicities remain important limitations. Zidesamtinib (Jideytro ®, NVL-520) is a next-generation, brain-penetrant, tropomyosin receptor kinase (TRK)-sparing ROS1 inhibitor designed to retain activity against resistance mutations, including G2032R. In preclinical models, it demonstrated potent, selective ROS1 inhibition, broad resistance coverage, and durable intracranial activity. Administered orally at 100 mg once daily, zidesamtinib exhibits a favorable pharmacokinetic profile. Data from the ARROS-1 phase 1/2 trial demonstrated durable clinical efficacy and manageable safety in previously treated ROS1-positive NSCLC, including patients with CNS metastases and G2032R resistance. These results led to its accelerated FDA approval on July 22, 2026, for patients previously treated with a ROS1-targeted tyrosine kinase inhibitor.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.